RECURRENT GRADE 3B FOLLICULAR LYMPHOMA
Clinical trials for RECURRENT GRADE 3B FOLLICULAR LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT GRADE 3B FOLLICULAR LYMPHOMA trials appear
Sign up with your email to follow new studies for RECURRENT GRADE 3B FOLLICULAR LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Engineered immune cells take on HIV-Linked cancers in first human trial
Disease control Recruiting nowThis study tests a CAR-T cell therapy (axicabtagene ciloleucel) in 20 HIV-positive adults whose aggressive B-cell lymphoma has come back or stopped responding to standard treatment. The therapy uses a patient's own immune cells, modified to recognize and attack cancer cells. The …
Matched conditions: RECURRENT GRADE 3B FOLLICULAR LYMPHOMA
Phase: PHASE1 • Sponsor: AIDS Malignancy Consortium • Aim: Disease control
Last updated Jun 22, 2026 12:03 UTC
-
New drug duo aims to outsmart tough lymphoma
Disease control Recruiting nowThis trial tests a combination of two drugs, epcoritamab and ibrutinib, for people with aggressive B-cell non-Hodgkin lymphoma that has returned or not responded to treatment. Epcoritamab helps immune cells attack lymphoma cells, while ibrutinib blocks signals that help cancer ce…
Matched conditions: RECURRENT GRADE 3B FOLLICULAR LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Yazeed Sawalha • Aim: Disease control
Last updated Jun 22, 2026 12:00 UTC
-
New combo therapy aims to boost immune attack on Hard-to-Treat lymphoma
Disease control Recruiting nowThis study tests whether adding an experimental drug (ST-067) to standard CAR T-cell therapy can safely and effectively treat adults with large B-cell lymphoma that has returned or not responded to prior treatments. About 33 participants will receive the combination to see if it …
Matched conditions: RECURRENT GRADE 3B FOLLICULAR LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 18, 2026 11:48 UTC
-
New drug duo takes on tough lymphoma
Disease control Recruiting nowThis study tests whether combining two targeted drugs (loncastuximab tesirine and mosunetuzumab) can shrink or control aggressive B-cell lymphomas that have returned or stopped responding to prior treatments. About 36 adults will receive the drug combination, and researchers will…
Matched conditions: RECURRENT GRADE 3B FOLLICULAR LYMPHOMA
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 12, 2026 12:03 UTC
-
New combo may help more lymphoma patients reach potentially curative CAR-T
Disease control Recruiting nowThis study tests whether giving two drugs, golcadomide and rituximab, before CAR-T cell therapy can help control aggressive B-cell non-Hodgkin lymphoma that has returned or not responded to prior treatment. The goal is to keep the disease in check so more patients can qualify for…
Matched conditions: RECURRENT GRADE 3B FOLLICULAR LYMPHOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 11, 2026 11:57 UTC
-
New drug may help more patients get Life-Saving CAR-T therapy
Disease control Recruiting nowThis study tests whether giving the drug odronextamab before CAR-T cell therapy can help control aggressive large B-cell lymphomas that have returned or not responded to prior treatment. About 27 adults will receive odronextamab to slow disease progression and increase the chance…
Matched conditions: RECURRENT GRADE 3B FOLLICULAR LYMPHOMA
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Jun 10, 2026 13:27 UTC